VCBeat Health Contact Us
Home Oricell and Weicheng Pharma Secure Over $100M Each in Same-Day Funding Rounds Ahead of IPO Filings

Oricell and Weicheng Pharma Secure Over $100M Each in Same-Day Funding Rounds Ahead of IPO Filings

Apr 14, 2026 18:05 CST Updated 18:05
Oricell Therapeutics

Developer of Tumor Immunocyte Products

Vivatides Therapeutics

Small Nucleic Acid Drug Developer

Image
Recently, Oricell Therapeutics and Vivatides Therapeutics, a rising star in the small nucleic acid sector, both announced the completion of significant financing rounds, securing US$110 million and US$54 million respectively.

Qrigincell Therapeutics: The Technological Leader in the CAR-T Field
Image
Qrigincell Therapeutics' Pre-IPO financing round was co-led by Vivo Capital, Beijing Medical and Health Industry Investment Fund, and Qiming Venture Partners, with several well-known institutions following the investment.
The company has built a differentiated CAR-T product matrix based on its self-innovated OriAb antibody screening and engineering platform, OriArmoring structural enhancement platform, and OnGo(Fast) CMC rapid process expertise.
Qrigincell Therapeutics' OriArmoring technology platform significantly enhances the survival time and killing efficacy of CAR-T cells in the tumor microenvironment by optimizing the structural design of CAR molecules, strengthening the activation signals, and improving resistance to exhaustion.
The OriAb antibody screening platform is capable of discovering and optimizing antibody sequences with high affinity and high specificity, ensuring precise recognition of tumor cells by CAR-T cells. These technological breakthroughs have laid the foundation for Ori-C101 to demonstrate excellent data in clinical trials for hepatocellular carcinoma.
About Ori-C101
The core product Ori-C101 is an autologous CAR-T drug targeting GPC3 for the treatment of advanced hepatocellular carcinoma. It has completed investigator-initiated clinical trials and Phase I registrational clinical trials, and is about to launch pivotal clinical trials. Clinical data have demonstrated excellent efficacy and safety profiles, with related findings being presented multiple times at top international academic conferences such as ASCO.
Ori-C101 is expected to become the world's first approved CAR-T drug for hepatocellular carcinoma, ushering in a new era of CAR-T therapy for solid tumors.
In addition to Ori-C101, Qrigincell Therapeutics is also continuously incubating secretory, rapid-production, and multiple in vivo CAR-T projects.
Secretory CAR-T reshapes the tumor microenvironment and enhances therapeutic efficacy by secreting immunomodulatory factors; rapid production technology significantly shortens the traditional 2-3 week CAR-T preparation cycle, potentially improving patient accessibility; in vivo CAR-T projects aim to achieve the goal of directly generating CAR-T cells within the patient's body, further simplifying the treatment process.
Image
Figure: Oricell Therapeutics Pipeline

Vivatides Therapeutics: Extrahepatic Delivery Opens Growth Space
Image
Vivatides Therapeutics Announces $54 Million Oversubscribed Series A Financing, Co-led by Qiming Venture Partners and a Leading Industry Fund, with Active Participation from Highlight Capital, TF Capital, and Others. Founded in 2025, Vivatides Therapeutics has completed two rounds of financing in less than a year, reflecting the market's high expectations for extrahepatic small nucleic acid delivery technology.
About Vivatides Therapeutics
The core team members of Vivatides Therapeutics come from global small nucleic acid drug leaders such as Arrowhead, Ionis, and Alnylam, and have accumulated extensive experience in delivery technology R&D, sequence design, CMC production, and clinical translation. Dr. Zhou Keming, the founder of the company, has over 15 years of deep expertise in the nucleic acid drug field and has led multiple small nucleic acid projects through the entire process from early discovery to clinical development, possessing profound technical expertise and industry resources.
Based on a deep understanding of the mechanisms of action and delivery requirements of nucleic acid drugs, Vivatides Therapeutics has developed an extracellular liver delivery platform with differentiated advantages. This platform achieves breakthroughs in key dimensions such as ligand conjugation technology, delivery efficiency optimization, tissue targeting accuracy, and safety, enabling the efficient delivery of small nucleic acid drugs to target tissues outside the liver, offering possibilities for the treatment of various extracellular diseases with nucleic acid drugs.
Dr. Zhou Keming, founder of Vivatides Therapeutics, stated: "Extrahepatic targeted delivery is the core key for small nucleic acid technology to move from 'rare diseases' to 'common chronic diseases.' With the rise of extrahepatic delivery technologies, the indications for small nucleic acid drugs are rapidly expanding from rare diseases to chronic disease areas such as hyperlipidemia, hypertension, and cancer. This progress will push the market size of small nucleic acid drugs from tens of billions to trillions."
Source: Corporate official website


Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. BioOutlook assumes no responsibility for any losses incurred by any party due to the use of the content herein. If there are any objections, please contact the editor via the backstage for modifications.

图片


Paid Recommendation





✦

Boutique Conference

✦


图片
图片


✦

High-Quality Community

✦


图片


图片

Scan the QR code to follow us

Reply "Target Audience", let's chat with the小伙伴们 in the biopharmaceutical industry~"

图片

Forward, Like, Read